Portfolio Holdings Detail for ISIN IE00B52SFT06
| Stock Name / Fund | iShares MSCI USA UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares VII Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300Q7FFITMZ2PFZ28 |
| ETF Ticker | CU1(GBX) LSE |
| ETF Ticker | SXR4(EUR) F |
| ETF Ticker | CSUS.LS(USD) CXE |
| ETF Ticker | CSUS.MI(EUR) CXE |
| ETF Ticker | CSUSz(USD) CXE |
| ETF Ticker | SXR4.DE(EUR) CXE |
| ETF Ticker | CSUS(EUR) Euronext Amsterdam |
| ETF Ticker | CU1.L(GBP) LSE |
Holdings detail for REGN
| Stock Name | Regeneron Pharmaceuticals Inc |
| Ticker | REGN(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US75886F1075 |
| LEI | 549300RCBFWIRX3HYQ56 |
Show aggregate REGN holdings
News associated with REGN
- Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
- (RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
- Peek Under The Hood: JEPQ Has 10% Upside
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages
- Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
- LABU, INCY, UTHR, REGN: ETF Outflow Alert
- Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
- Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis
- Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
- Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00
- Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL
- Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
- Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
- Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
- We Did The Math SPYX Can Go To $58
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
- 409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors
- Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
- Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says
- Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
- Stocks Slump on Tariffs and Weak US Job Growth
- The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
- Stocks Slump on Tariffs and Weak US Job Growth
- The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
- Stocks Slump on Tariffs and Weak US Job Growth
- The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
- Stocks Slump on Tariffs and Weak US Job Growth
- The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
- Nasdaq 100 Movers: MRVL, REGN
- In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value.
And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC
- Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
- Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
- Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
- Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
- Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
- Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
- Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.
- Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
- Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
- Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
- Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
- Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
- Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00
- Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
- Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
- Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.
- D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
- Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
- DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
- DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
- Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
- Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52
iShares MSCI USA UCITS ETF USD (Acc) REGN holdings
| Date | Number of REGN Shares Held | Base Market Value of REGN Shares | Local Market Value of REGN Shares | Change in REGN Shares Held | Change in REGN Base Value | Current Price per REGN Share Held | Previous Price per REGN Share Held |
|---|
| 2025-12-02 (Tuesday) | 5,483 | USD 4,068,386 | USD 4,068,386 | -17 | USD -57,219 | USD 742 | USD 750.11 |
| 2025-12-01 (Monday) | 5,500 | USD 4,125,605 | USD 4,125,605 | 0 | USD -165,440 | USD 750.11 | USD 780.19 |
| 2025-11-28 (Friday) | 5,500 | USD 4,291,045 | USD 4,291,045 | 0 | USD -24,310 | USD 780.19 | USD 784.61 |
| 2025-11-27 (Thursday) | 5,500 | USD 4,315,355 | USD 4,315,355 | 0 | USD 0 | USD 784.61 | USD 784.61 |
| 2025-11-26 (Wednesday) | 5,500 | USD 4,315,355 | USD 4,315,355 | 0 | USD -14,905 | USD 784.61 | USD 787.32 |
| 2025-11-25 (Tuesday) | 5,500 | USD 4,330,260 | USD 4,330,260 | 0 | USD 142,285 | USD 787.32 | USD 761.45 |
| 2025-11-24 (Monday) | 5,500 | USD 4,187,975 | USD 4,187,975 | 170 | USD 159,028 | USD 761.45 | USD 755.9 |
| 2025-11-21 (Friday) | 5,330 | USD 4,028,947 | USD 4,028,947 | 68 | USD 150,853 | USD 755.9 | USD 737 |
| 2025-11-20 (Thursday) | 5,262 | USD 3,878,094 | USD 3,878,094 | 0 | USD 180,223 | USD 737 | USD 702.75 |
| 2025-11-19 (Wednesday) | 5,262 | USD 3,697,871 | USD 3,697,871 | 17 | USD -106,537 | USD 702.75 | USD 725.34 |
| 2025-11-18 (Tuesday) | 5,245 | USD 3,804,408 | USD 3,804,408 | 561 | USD 505,420 | USD 725.34 | USD 704.31 |
| 2025-11-17 (Monday) | 4,684 | USD 3,298,988 | USD 3,298,988 | 0 | USD 50,634 | USD 704.31 | USD 693.5 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of REGN by Blackrock for IE00B52SFT06
Show aggregate share trades of REGN| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-12-02 | SELL | -17 | | | 742.000* | | 645.89 Profit of 10,980 on sale |
| 2025-11-24 | BUY | 170 | 773.130 | 756.640 | 758.289 | USD 128,909 | 642.16 |
| 2025-11-21 | BUY | 68 | | | 755.900* | | 641.61 |
| 2025-11-19 | BUY | 17 | | | 702.750* | | 640.84 |
| 2025-11-18 | BUY | 561 | | | 725.340* | | 640.42 |
| 2025-11-03 | BUY | 17 | 657.460 | 627.500 | 630.496 | USD 10,718 | 638.97 |
| 2025-10-29 | BUY | 34 | 652.910 | 659.980 | 659.273 | USD 22,415 | 638.75 |
| 2025-10-24 | BUY | 17 | 577.950 | 582.700 | 582.225 | USD 9,898 | 639.36 |
| 2025-10-17 | BUY | 17 | 578.050 | 579.040 | 578.941 | USD 9,842 | 640.72 |
| 2025-10-03 | BUY | 34 | 600.000 | 618.010 | 616.209 | USD 20,951 | 642.08 |
| 2025-10-01 | BUY | 17 | 599.940 | 615.390 | 613.845 | USD 10,435 | 642.32 |
| 2025-09-30 | BUY | 34 | 562.270 | 574.040 | 572.863 | USD 19,477 | 642.77 |
| 2025-09-29 | BUY | 17 | 560.750 | 564.910 | 564.494 | USD 9,596 | 643.24 |
| 2025-09-24 | BUY | 187 | 576.980 | 577.980 | 577.880 | USD 108,064 | 644.59 |
| 2025-09-15 | BUY | 17 | 572.590 | 573.690 | 573.580 | USD 9,751 | 646.05 |
| 2025-09-12 | SELL | -17 | 560.000 | 570.000 | 569.000 | USD -9,673 | 646.56 Profit of 1,318 on sale |
| 2025-09-05 | BUY | 17 | 573.380 | 577.750 | 577.313 | USD 9,814 | 649.14 |
| 2025-07-17 | SELL | -17 | 550.000 | 554.480 | 554.032 | USD -9,419 | 652.45 Profit of 1,673 on sale |
| 2025-07-15 | SELL | -17 | 547.960 | 574.750 | 572.071 | USD -9,725 | 653.80 Profit of 1,389 on sale |
| 2025-07-10 | BUY | 34 | 559.760 | 566.370 | 565.709 | USD 19,234 | 655.53 |
| 2025-07-02 | BUY | 34 | 547.740 | 551.500 | 551.124 | USD 18,738 | 660.00 |
| 2025-06-27 | BUY | 51 | 521.000 | 531.210 | 530.189 | USD 27,040 | 661.91 |
| 2025-05-28 | SELL | -17 | 591.850 | 606.000 | 604.585 | USD -10,278 | 686.54 Profit of 1,393 on sale |
| 2025-04-14 | BUY | 31 | 571.060 | 574.720 | 574.354 | USD 17,805 | 723.48 |
| 2025-04-11 | BUY | 31 | 554.180 | 555.530 | 555.395 | USD 17,217 | 725.36 |
| 2025-04-04 | SELL | -682 | 573.450 | 612.990 | 609.036 | USD -415,363 | 734.78 Profit of 85,757 on sale |
| 2025-03-19 | SELL | -31 | 672.360 | 674.570 | 674.349 | USD -20,905 | 748.34 Profit of 2,294 on sale |
| 2025-03-17 | SELL | -31 | 678.420 | 679.830 | 679.689 | USD -21,070 | 750.47 Profit of 2,194 on sale |
| 2025-03-12 | BUY | 62 | 689.500 | 712.460 | 710.164 | USD 44,030 | 753.58 |
| 2025-03-11 | BUY | 62 | 718.160 | 747.700 | 744.746 | USD 46,174 | 754.10 |
| 2025-03-10 | BUY | 186 | 744.830 | 748.290 | 747.944 | USD 139,118 | 754.24 |
| 2025-03-07 | BUY | 62 | 707.510 | 729.750 | 727.526 | USD 45,107 | 754.95 |
| 2025-03-06 | BUY | 31 | 698.440 | 701.000 | 700.744 | USD 21,723 | 755.82 |
| 2025-03-05 | BUY | 31 | 687.150 | 692.790 | 692.226 | USD 21,459 | 756.89 |
| 2025-03-04 | BUY | 93 | 675.490 | 697.460 | 695.263 | USD 64,659 | 758.18 |
| 2025-03-03 | BUY | 62 | 684.870 | 704.640 | 702.663 | USD 43,565 | 759.37 |
| 2025-02-27 | BUY | 155 | 702.780 | 721.000 | 719.178 | USD 111,473 | 761.32 |
| 2025-02-26 | BUY | 62 | 706.940 | 721.410 | 719.963 | USD 44,638 | 762.24 |
| 2025-02-18 | BUY | 93 | 680.000 | 689.950 | 688.955 | USD 64,073 | 769.31 |
| 2025-02-05 | BUY | 31 | 716.720 | 729.250 | 727.997 | USD 22,568 | 785.99 |
| 2025-01-31 | BUY | 31 | 672.980 | 688.000 | 686.498 | USD 21,281 | 793.82 |
| 2024-12-30 | BUY | 62 | 702.590 | 708.970 | 708.332 | USD 43,917 | 818.70 |
| 2024-11-20 | BUY | 124 | 743.350 | 750.690 | 749.956 | USD 92,995 | 869.45 |
| 2024-11-18 | BUY | 155 | 762.000 | 762.700 | 762.630 | USD 118,208 | 883.97 |
| 2024-11-12 | BUY | 31 | 821.000 | 831.000 | 830.000 | USD 25,730 | 888.17 |
| 2024-11-07 | BUY | 155 | 824.480 | 832.530 | 831.725 | USD 128,917 | 897.66 |
| 2024-10-24 | BUY | 31 | 928.900 | 952.020 | 949.708 | USD 29,441 | 957.41 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of REGN
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 208,659 | 1,635 | 312,812 | 66.7% |
| 2025-09-18 | 236,485 | 3,679 | 387,519 | 61.0% |
| 2025-09-17 | 229,191 | 716 | 370,895 | 61.8% |
| 2025-09-16 | 173,632 | 584 | 271,020 | 64.1% |
| 2025-09-15 | 204,491 | 251 | 334,496 | 61.1% |
| 2025-09-12 | 117,504 | 33 | 222,760 | 52.7% |
| 2025-09-11 | 125,478 | 3,137 | 286,516 | 43.8% |
| 2025-09-10 | 195,068 | 481 | 339,885 | 57.4% |
| 2025-09-09 | 129,168 | 994 | 274,520 | 47.1% |
| 2025-09-08 | 250,895 | 396 | 527,062 | 47.6% |
| 2025-09-05 | 170,149 | 290 | 289,566 | 58.8% |
| 2025-09-04 | 188,227 | 2,103 | 360,619 | 52.2% |
| 2025-09-03 | 185,679 | 344 | 438,111 | 42.4% |
| 2025-09-02 | 191,954 | 138 | 476,288 | 40.3% |
| 2025-08-29 | 133,226 | 685 | 236,726 | 56.3% |
| 2025-08-28 | 116,560 | 2,177 | 256,675 | 45.4% |
| 2025-08-27 | 113,719 | 465 | 243,836 | 46.6% |
| 2025-08-26 | 210,376 | 450 | 400,199 | 52.6% |
| 2025-08-25 | 149,130 | 68 | 363,377 | 41.0% |
| 2025-08-22 | 211,822 | 3,244 | 701,770 | 30.2% |
| 2025-08-21 | 257,492 | 3,416 | 446,439 | 57.7% |
| 2025-08-20 | 327,738 | 572 | 559,133 | 58.6% |
| 2025-08-19 | 118,472 | 2,191 | 324,311 | 36.5% |
| 2025-08-18 | 146,282 | 388 | 277,909 | 52.6% |
| 2025-08-15 | 209,923 | 3,375 | 441,752 | 47.5% |
| 2025-08-14 | 157,569 | 3,623 | 429,327 | 36.7% |
| 2025-08-13 | 111,342 | 233 | 362,786 | 30.7% |
| 2025-08-12 | 117,647 | 171 | 310,775 | 37.9% |
| 2025-08-11 | 129,513 | 2,676 | 284,757 | 45.5% |
| 2025-08-08 | 128,559 | 1,038 | 431,841 | 29.8% |
| 2025-08-07 | 166,648 | 1,560 | 352,877 | 47.2% |
| 2025-08-06 | 176,311 | 624 | 397,089 | 44.4% |
| 2025-08-05 | 154,257 | 115 | 353,744 | 43.6% |
| 2025-08-04 | 200,758 | 1,913 | 409,897 | 49.0% |
| 2025-08-01 | 349,775 | 3,745 | 728,720 | 48.0% |
| 2025-07-31 | 222,350 | 476 | 549,344 | 40.5% |
| 2025-07-30 | 106,839 | 1,689 | 231,761 | 46.1% |
| 2025-07-29 | 149,359 | 276 | 292,667 | 51.0% |
| 2025-07-28 | 103,687 | 1,380 | 245,287 | 42.3% |
| 2025-07-25 | 103,783 | 556 | 259,069 | 40.1% |
| 2025-07-24 | 156,974 | 2,397 | 291,677 | 53.8% |
| 2025-07-23 | 168,734 | 1,708 | 355,372 | 47.5% |
| 2025-07-22 | 116,324 | 617 | 304,880 | 38.2% |
| 2025-07-21 | 98,482 | 900 | 250,107 | 39.4% |
| 2025-07-18 | 183,174 | 1,051 | 391,909 | 46.7% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy